Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
This study has been completed.
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00878072
First received: April 7, 2009
Last updated: May 1, 2012
Last verified: May 2012
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | April 7, 2009 | ||||
Last Updated Date | May 1, 2012 | ||||
Start Date ICMJE | March 2009 | ||||
Primary Completion Date | June 2010 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Safety: Frequency of adverse events and laboratory abnormalities [ Time Frame: 48 hours, 4 days ] [ Designated as safety issue: Yes ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT00878072 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis | ||||
Official Title ICMJE | A Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis | ||||
Brief Summary | This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis. Eight of the 50 adolescents will also participate in the pharmacokinetics (PK) assessment of famciclovir single 1500 mg dose |
||||
Detailed Description | Uncontrolled study |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 2 Phase 3 |
||||
Study Design ICMJE | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
||||
Condition ICMJE | Herpes Labialis | ||||
Intervention ICMJE | Drug: Famciclovir
Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose. |
||||
Study Arm (s) | Experimental: Famciclovir
Intervention: Drug: Famciclovir |
||||
Publications * | Block SL, Yogev R, Waldmeier F, Hamed K. Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis. Pediatr Infect Dis J. 2011 Jun;30(6):525-8. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Enrollment ICMJE | 53 | ||||
Completion Date | |||||
Primary Completion Date | June 2010 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 12 Years to 18 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00878072 | ||||
Other Study ID Numbers ICMJE | CFAM810B2305 | ||||
Has Data Monitoring Committee | |||||
Responsible Party | Novartis ( Novartis Pharmaceuticals ) | ||||
Study Sponsor ICMJE | Novartis Pharmaceuticals | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Novartis | ||||
Verification Date | May 2012 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |